Shares of Milestone Therapeutics MIST fell 21.67% during market hours on Oct 17, after rising 41% in premarket, post the company’s announcement of top-line results from a late-stage study evaluating ...

Enrollment of the first patient in Europe represents continued progress in the global execution of ReVeRA-301 as we advance our pivotal Phase 3 program,” said David Bharucha, M.D., PhD, FACC, Chief ...

Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study Additional studies expected to evaluate the potential of MRT-6160 (DDY391) across immune-mediated ...